SCP-799
Unknown
~
medium confidence
SCP-799
Expected annual
$679K
One-time setup
$728K
Annual recurring
$662K
Personnel
1.48
Initial capital is approximately $728,000 driven primarily by containment cell construction, site HVAC upgrades and monitoring/imaging equipment; ongoing annual operations are approximately $661,734/year driven by staff wages, an active research/surveillance program, emergency readiness and a risk reserve.
One-Time Capital Costs
Total: $728K
Annual Recurring Costs
Total: $662K/yr
Cost Scenarios
📊
Baseline
(baseline)
$662K/yr
Normal year with routine operations, surveillance, and no major incidents.
no breaches
routine sampling and maintenance
occasional transfers only
🚨
Minor Incident
$712K/yr
Small civilian exposure or single-specimen incident requiring local response, amnestics and limited reparations.
local exposure
single witness requiring amnestic
small legal/PR response
🚨
Major Breach
$962K/yr
Containment breach or multi-victim incident requiring major emergency response, multiple medical treatments and significant legal action.
multi-victim exposure
large retrieval/transport operation
extensive legal claims
🚨
Catastrophic Breach
$1.9M/yr
Severe multi-site exposure, protracted litigation or public revelation requiring large-scale remediation, litigation settlements, and program scaling.
public exposure with multiple casualties
lawsuits or media exposure
mass remediation required
Personnel
1.48 total
| Role | Count | Notes |
|---|---|---|
| Research Scientist | 0.4 | Program-level supervisory scientist (0.25–0.5 FTE allocated to program; budgeted as partial-year effort). |
| Research / Containment Technician | 0.08 | Per-specimen incremental technician time (0.02 FTE/specimen × 4 specimens ≈ 0.08 FTE; ~42 hours/year per specimen aggregated). |
| Security Officer / MTF Agent | 1.0 | One dedicated security guard post for the containment wing (salary+benefits budgeted). |
Confidence Notes
Analyst notes provide per-item ranges and clear drivers (per-cell capital, per-specimen recurring costs, and event-driven legal/response costs), enabling midpoint estimates; uncertainty remains in specimen count scaling, frequency of adverse incidents, and program ambition for research/surveillance, so confidence is medium.